Clinigen Finalises Acquisitions of SSI Strategy
Creates a seamless path from clinical strategy to global commercialisation for biopharma innovators
LONDON, UK - 21 November 2025:
Clinigen, the global pathfinder accelerating patient access to critical medicines across the lifecycle, today confirmed the close of its acquisition of SSI Strategy, a trusted strategic consulting partner to biotech innovators.
The completion of this transaction brings together SSI’s renowned strategic advisory depth, established U.S. and European footprint, and pioneering partnership models with Clinigen’s global operational reach and decades of experience in clinical trial supply, managed access, and commercialisation. This combination creates a comprehensive global partner for the biopharma industry, uniquely positioned to navigate the entire product lifecycle from early-stage strategy to global specialist commercialisation, de-risking development and accelerating patient access to critical therapies.
The deal adds the specialised capabilities of over 200 employees, including 145 expert consultants, spanning Medical, Clinical, and Regulatory competencies, and a deep client base of over 280 biopharma companies. SSI’s CEO, Doug Locke will continue to lead the SSI organisation and will work alongside Clinigen’s leadership to expand the impact of their combined services for clients in key international markets.
This strengthened market standing positions Clinigen to serve the $12-13 billion global market for pharmaceutical lifecycle services, expected to grow by nearly 10% annually through 2030.
Dr. Varun Sethi, CEO, Clinigen said, “The completion of this acquisition marks an exciting new chapter in our Global Pathfinder mission. Where others see complexity, we see a path. By matching SSI’s strategic depth with our global expertise and infrastructure, we become an even stronger, more complete partner for the entire product lifecycle.”
Doug Locke, CEO of SSI Strategy, said, “Our purpose at SSI has always been simple: to help build better biotechs. Joining Clinigen is a confirmation of that mission; in them, we recognised fellow pathfinders committed to innovation. We have built our reputation on navigating the toughest development challenges and derisking the path to market. This move gives us the reach to amplify that impact, supporting our client partners’ most critical milestones with greater reach, while maintaining the specialised expertise and trusted partnership they rely on.”
For media enquiries, please contact:
Brett Dunbar, Clinigen
Global Communications Manager
media@clinigengroup.com
Fight or Flight on behalf of Clinigen
clinigen@fightorflight.com
About Clinigen
Clinigen is a global pharmaceutical services company trusted by over 1,000 pharma and biotech partners. With more than 35 years of experience, we accelerate access to critical medicines at every stage of the product lifecycle. As pathfinders, our team of over 1,100 specialists expertly navigate the complexities of clinical trial supply, early access programs, regulatory services, and long-term commercialisation through both licensed and unlicensed pathways. Operating across five continents, we deliver innovative solutions to over 130 countries each year. Whatever the challenge, we find a way.
Explore our services at www.clinigen.com
About SSI Strategy
SSI Strategy is dedicated to building better biotechs by combining sharp business acumen with deep expertise in Clinical Development & Operations, Regulatory Affairs, Pharmacovigilance, Medical Affairs, Quality, and more. With an adaptive model that scales to each client’s needs, SSI Strategy works as an embedded extension of internal teams – empowering employees, enhancing performance, and accelerating progress. From concept to commercialization, SSI Strategy delivers the strategic insight, technical expertise, and collaborative support biotech leaders need to overcome challenges and bring life-saving therapies to patients.